Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7036 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 |
filingDate |
2022-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_586c3de878149e2f2d6f797c69ef4d09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92fc3d636e32248e081274c62c15aa20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e0e5945c9044336e031c13d5e33c4e9 |
publicationDate |
2022-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2022362329-A1 |
titleOfInvention |
Treating acute liver disease with tlr-mik inihibitors |
abstract |
Methods of treating acute liver disease acute liver diseases are provided. Accordingly, there is provided a method of treating acute liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of binding a component of a TLR-MYC signaling pathway selected from the group consisting of MYC, MYD88, TRIF and p38 and inhibiting expression and/or activity of the component. |
priorityDate |
2020-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |